🧬Immuno-Oncology Services
At Innatura Scientific, our Immuno-Oncology Division is dedicated to advancing the next generation of cancer immunotherapies by decoding immune resistance and reactivating the body’s natural defenses. We offer end-to-end discovery, translational, and preclinical solutions, specialized in TIGIT-targeted immune checkpoint modulation and beyond.
Harnessing cutting-edge immunobiology, high-throughput screening, and advanced tumor-immune modeling, we accelerate the path from novel target identification to IND-enabling studies, helping our partners develop smarter, more durable immunotherapies.
🎯 Focus Area: TIGIT – The Next-Gen Checkpoint Target
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a promising immune checkpoint expressed on exhausted T cells, regulatory T cells (Tregs), and natural killer (NK) cells within the tumor microenvironment (TME). By suppressing CD226-mediated immune activation, TIGIT promotes immune evasion and tumor persistence.
Our TIGIT-Centric Offerings:
-
Lead Optimization & Screening of small molecules, antibodies, and fusion proteins targeting the TIGIT/CD155/CD112 axis
-
In vitro Assays: T-cell activation, Treg suppression, NK cell cytotoxicity models
-
Custom Reporter Cell Lines: TIGIT, PD-1, and dual-checkpoint engineered systems
-
Flow Cytometry & Immunophenotyping: Exhaustion markers, cytokine profiling, TIL characterization
-
In Vivo Tumor Models: Syngeneic, humanized, and checkpoint-expressing mouse models to evaluate anti-TIGIT efficacy
-
Checkpoint Combination Strategy: TIGIT + PD-1/PD-L1, CTLA-4, or LAG-3 co-targeting frameworks
🧪 Broader Immuno-Oncology Capabilities
We enable a full spectrum of preclinical immuno-oncology R&D, including:
✅ Checkpoint Target Discovery & Validation
✅ CAR-T/NK Cell Functional Testing
✅ Neoantigen Prediction & Peptide Vaccine Support
✅ TME Modulation Assays: MDSCs, TAMs, CAFs
✅ Biomarker Discovery: Gene expression, proteomics, and cytokine release profiling
✅ Immune Cell Engineering & Co-culture Platforms
💼 Who We Serve
-
Biotech Startups seeking fast-track validation of IO assets
-
Pharma & Biopharma Leaders aiming to expand their immunotherapy pipelines
Academic Consortia and CRO partners exploring novel immune targets and translational models
🌐 Why Choose Innatura?
🔬 Scientific Rigor: Built by a team of immunologists, chemists & translational oncology experts
🚀 Speed & Flexibility: Agile project management, rapid feasibility, and customizable study plans
🤝 Integrated Collaboration: From discovery to IND — we co-create, adapt, and scale with you
🔐 IP Respect & Data Integrity: Robust security and regulatory-grade documentation standards
🧭The Future of Immuno-Oncology Starts Here
Whether you're developing monoclonal antibodies, immune-modulatory small molecules, or next-gen cellular therapies, our team is your strategic partner in unlocking the immune system's full therapeutic potential.
📧 Let’s connect: info@innaturascientific.com
📞 +91-9966161722
🌐 www.innaturascientific.com
